Product pipeline      Malaria      Hepatitis C      Ebola and Marburg      Influenza      Respiratory Syncytial Virus      

Send by emailPrint this page

Medical need

Influenza is a viral infection that affects mainly the nose, throat and bronchi, which usually lasts for about a week, but can be fatal in certain patient populations and is responsible for up to 500,000 annual fatalities worldwide. The fast mutation rate of this pathogen requires that new flu vaccines be developed each year prior to the start of the next flu season. While this is a very successful approach and has significantly decreased mortality associated with influenza, it does leave the population susceptible to outbreak of “pandemic” flu strains, those that are not covered by the current seasonal vaccine, and which can cause excessively high mortality rates.


Background and rationale for a genetic universal influenza vaccine

Our influenza vaccine, currently in preclinical development, aims at providing cross-strain protection against most human influenza strains as well as against avian and swine influenza. This approach would overcome the need to create a customized flu vaccine for each new flu season, and would provide protection against the outbreak of a pandemic flu strain. This vaccine consists of our proprietary adenoviral vectors, encoding optimised influenza antigens.